阿斯利康在英国投资 6.5 亿英镑用于大流行防范和研发扩张。 AstraZeneca invests £650m in UK for pandemic preparedness and R&D expansion.

阿斯利康将在英国投资 6.5 亿英镑，以加强大流行病防范并扩大其研究、开发和制造能力。 AstraZeneca is investing £650 million in the UK to enhance pandemic preparedness and expand its research, development, and manufacturing capabilities. 该投资包括 4.5 亿英镑用于在利物浦斯皮克建立疫苗生产设施，以及 2 亿英镑用于扩大其全球总部所在地剑桥的业务。 The investment includes £450 million for a vaccine production facility in Speke, Liverpool, and £200 million to expand its presence in Cambridge, home to its global headquarters. 对英国生命科学行业的这一承诺凸显了阿斯利康对英国专业知识和资源的持续信心。 This commitment to the UK's life sciences sector highlights AstraZeneca's ongoing confidence in the nation's expertise and resources.